# First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

> **NCT04504669** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 60 (actual)

## Conditions studied

- Clear Cell Renal Cell Cancer
- Non-Small-Cell Lung Cancer
- Triple Negative Breast Neoplasms
- Squamous Cell Cancer of Head and Neck
- Small Cell Lung Cancer
- Gastroesophageal Cancer
- Melanoma
- Cervical Cancer
- Advanced Solid Tumours

## Interventions

- **DRUG:** AZD8701
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT04504669
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-18
- **Primary completion:** 2024-10-07
- **Final completion:** 2024-10-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504669, "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT04504669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*